Two Sigma Securities, LLC Affimed N.V. Transaction History

Two Sigma Securities, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.32 - $0.62 $1,480 - $2,868	4,626 Added 5.84%	83,880 $52,000
Q3 2023 Nov 14, 2023	BUY	$0.46 - $0.65 $1,872 - $2,646	4,071 Added 5.41%	79,254 $38,000
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.08 $42,854 - $81,197	75,183 New	75,183 $45,000
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $11,550 - $25,725	10,500 Added 67.31%	26,099 $32,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $30,574 - $51,788	15,599 New	15,599 $32,000
Q1 2020 May 15, 2020	SELL	$1.44 - $3.02 $19,717 - $41,352	-13,693 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $30,809 - $42,037	13,693 New	13,693 $38,000
Q1 2018 May 15, 2018	SELL	$1.25 - $2.65 $130,640 - $276,956	-104,512 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$1.23 - $2.3 $128,549 - $240,377	104,512	104,512 $136,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.